Lancet:右苯丙胺缓释剂治疗难治性海洛因依赖患者效果良好

2016-03-24 崔倩 译 MedSci原创

海洛因辅助治疗对于美沙酮治疗难治性海洛因依赖患者是有效的,但是继续依赖可卡因仍然是个问题。缓释右旋苯丙胺对于可卡因成瘾是一种很有潜力的激动剂药物,该研究的目的是评估其接受性,疗效和安全性。原始出处:Mascha Nuijten,Peter Blanken,Ben van de Wetering,et al.Sustained-release dexamfetamine in the treatme

海洛因辅助治疗对于美沙酮治疗难治性海洛因依赖患者是有效的,但是继续依赖可卡因仍然是个问题。右苯丙胺缓释剂对于可卡因成瘾是一种很有潜力的激动剂药物,该研究的目的是评估其接受性,疗效和安全性。

在这个多中心、随机、双盲、安慰剂对照试验中,难治性患者,正在使用或减少使用可卡因且被表明有至少两次早期治疗失败的经历,并定期使用可卡因(≥8天/月)的患者被招募到此研究中,他们来自荷兰的4个海洛因辅助治疗中心。符合条件的患者被随机分配(1:1)到一个12周的疗程里,口服右苯丙胺缓释剂60mg/天或安慰剂加入到处方药物美沙酮和二乙酰吗啡中。随机化是由协作药剂师进行,使用具有分层计算机产生的随机数序列进行分层。在整个研究过程中,患者、工作人员,以及研究人员都不知道治疗随机分配情况。主要成果是研究治疗期间使用可卡因的自我报告的天数,每4周进行评估。主要和安全分析是在意向性治疗人群中进行的。

在2014年8月8日和2015年2月27日之间,111例患者被评定为合格,其中73例患者入选,并随机分配;38例患者被分配到右苯丙胺缓释剂组,35例患者分配安慰剂组。右苯丙胺缓释剂治疗比使用安慰剂治疗能够显著减少可卡因使用的天数(分别为平均44.9天[SD 29.4] vs 60.6天[24.3],[差异的95%CI 3.1至28.4];p=0.031,科恩标准化效应d=0.58)。右苯丙胺缓释剂组的28例(74%)患者有一个或一个以上的不良事件,安慰剂组有16(46%)例患者被报告出现不良事件。大多数不良反应是短暂的,耐受性良好。

右苯丙胺缓释剂对于海洛因依赖且有难治性合并症患者是广泛有效的,安全的激动剂药物。未来的研究应着眼于在慢性可卡因依赖患者和其他兴奋剂依赖患者中重复这些发现,并且增加更多的常规治疗的设置,包括战略,优化治疗依从性例如药物一样管理干预措施和应急管理。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828440, encodeId=408b182844042, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 04:32:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523495, encodeId=a33c15234955e, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Fri Mar 25 22:32:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528310, encodeId=193e15283102f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 25 22:32:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-10-11 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828440, encodeId=408b182844042, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 04:32:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523495, encodeId=a33c15234955e, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Fri Mar 25 22:32:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528310, encodeId=193e15283102f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 25 22:32:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828440, encodeId=408b182844042, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 04:32:00 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523495, encodeId=a33c15234955e, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Fri Mar 25 22:32:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528310, encodeId=193e15283102f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 25 22:32:00 CST 2016, time=2016-03-25, status=1, ipAttribution=)]
    2016-03-25 freve